ATXI Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Avenue Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$15.00 |
| 52 Week Low | US$1.60 |
| Beta | -0.27 |
| 1 Month Change | 1.64% |
| 3 Month Change | -7.92% |
| 1 Year Change | -85.72% |
| 3 Year Change | -99.82% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Avenue Therapeutics shares slide on pricing $12M securities offering
Oct 07Avenue Therapeutics up 4% on 1-for-15 reverse stock split
Sep 22Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine
Jun 14We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Mar 19
How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?
Jan 23We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate
Dec 19Avenue Therapeutics issues regulatory update for IV tramadol
Dec 17Shareholder Returns
| ATXI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.0% | 0.5% | 0.7% |
| 1Y | -85.7% | 2.2% | 23.0% |
Return vs Industry: ATXI underperformed the US Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: ATXI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| ATXI volatility | |
|---|---|
| ATXI Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATXI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ATXI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Alix MacLean | www.avenuetx.com |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Avenue Therapeutics, Inc. Fundamentals Summary
| ATXI fundamental statistics | |
|---|---|
| Market cap | US$3.74m |
| Earnings (TTM) | -US$18.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs ATXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATXI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.28m |
| Earnings | -US$18.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 09:24 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avenue Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | B. Riley Wealth |
| Antonio Arce | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |